The present invention relates to the use of PDE1C as a novel target for
the identification of compounds, which can be used for the treatment of
pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases
outside the lung. The present invention further relates to the use of
PDE1C inhibitors in the manufacture of pharmaceutical compositions for
use in the therapy of those diseases.
